Seres Therapeutics Inc. (MCRB) Live Share Price, Invest From India

Seres Therapeutics Inc. Stock Performance

as on August 8, 2026 at 2:15 pm IST

Day's Low
Day's High
$4.82
Day's Price Range
$5.19
$4.87
1.03%
Downside
6.57%
Upside
52 Week's Low
52 Week's High
$4.59
52-Week Price Range
$29.98
$4.87
5.75%
Downside
515.61%
Upside

Seres Therapeutics Inc. share price movements today

Previous Close: $4.82
Open: $4.99
Volume: 249.8K
Day's Low - High: $4.82 - $5.19
52 Week Low - High: $4.59 - $29.98

Seres Therapeutics Inc. Historical Returns

1 Month Return: -28.49 %
3 Month Return: -37.4 %
1 Year Return: -66.08 %
3 Year Return: -94.02 %
5 Year Return: -96.54 %

Seres Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Seres Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$49.8M

EPS (TTM)

-4.36

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

-0.11

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-66.57%

Seres Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Seres Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Seres Therapeutics Inc.	BUY	$49.8M	-96.54%	NA	0.00%	NA
Revolution Medicines Inc.	BUY	$41.9B	624.31%	NA	0.00%	NA
Vertex Pharmaceuticals Inc.	BUY	$122.9B	141.53%	27.85	35.00%	NA
Regeneron Pharmaceuticals Inc.	BUY	$79.1B	25.76%	18.83	27.87%	0.48%

Stock Returns calculator for Seres Therapeutics Inc. Stock including INR - Dollar returns

The Seres Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Seres Therapeutics Inc. investment value today

Current value as on today

₹37,292

Returns

-₹62,708

(-62.71%)

Returns from Seres Therapeutics Inc. Stock

-₹65,728 (-65.73%)

Dollar Impact

₹3,021 (+3.02%)

Analyst Recommendation on Seres Therapeutics Inc. Stock

Based on 13 analysts

BUY

76.92%

Buy

15.38%

Hold

7.69%

Sell

Based on 13 analysts, 76.92% of analysts recommend a 'BUY' rating for Seres Therapeutics Inc.. Average target price of $17

Seres Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Seres Therapeutics Inc..

What analysts predicted

71.35%UPSIDE

Target Price

$17

Current Price

$4.87

Analyzed by

13 Analysts

Target

$17.00

Seres Therapeutics Inc. target price $17, a slight upside of 71.35% compared to current price of $4.87. According to 13 analysts rating.

Indian Investors' Interest in Seres Therapeutics Inc. Stock

Search interest for Seres Therapeutics Inc. Stock has decreased by -5% in the last 30 days, reflecting a downward trend in search activity.

Time period: July 10, 2026 to August 9, 2026

Change:-5% versus previous 30 day period

Seres Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	5	-	-	0	0	0	0
Gross Profit	-19	-1	-1	-5	-3	-1	-13	14	0	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-40	-32	88	-15	32	-19	8	-15	-19	4
Net Profit Margin	0.00%	0.00%	0.00%	-262.45%	0.00%	0.00%	2337.32%	-3501.14%	-5562.29%	622.42%

Seres Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	21	32	28	34	33	144	7	126	-	0
Gross Profit	-60	-57	28	34	-57	144	6	-19	-3	-3
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-91	-89	-98	-70	-89	-65	-250	-113	-146	5
Net Profit Margin	-420.74%	-278.44%	-350.03%	-203.68%	-268.33%	-45.25%	-3509.50%	-90.02%	0.00%	721.93%

Global Institutional Holdings in Seres Therapeutics Inc.

Funds	Holdings
Marshall Wace Asset Management Ltd	1.44%
Geode Capital Management, LLC	0.77%
Vanguard Group Inc	3.35%
UBS Group AG	0.07%
Barclays PLC	0.07%

See all

Insights on Seres Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 358.0K → 736.0K (in $), with an average increase of 51.4% per quarter
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -19.91M → 4.58M (in $), with an average increase of 534.7% per quarter
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 465.2% return, outperforming this stock by 531.3%
NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 567.8% return, outperforming this stock by 661.8%
NEGATIVE IMPACT
Price Dip
In the last 1 month, MCRB stock has moved down by -28.5%

About Seres Therapeutics Inc.

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Organisation	Seres Therapeutics Inc.
Headquarters	101 Cambridgepark Drive, Cambridge, MA, United States, 02140
Industry	Biotechnology
CEO	Mr. Richard N. Kender B.S., M.B.A.
E-voting on shares	Click here to vote

Key Management of Seres Therapeutics Inc.

Name	Title
Ms. Kelly Brady M.S.	Executive VP & COO
Mr. Chris McChalicher	Executive VP & CTO
Dr. Dennis M. Walling M.D.	Senior VP of Clinical Development & Head of Clinical Research
Ms. Ann Kurowski	Senior Vice President of Regulatory Affairs
Mr. Richard N. Kender B.S., M.B.A.	Interim CEO & Executive Chair
Dr. Matthew R. Henn Ph.D.	President & Chief Scientific Officer
Ms. Marella Thorell CPA	Executive VP, CFO & Treasurer
Mr. Thomas J. DesRosier Esq., J.D.	Executive VP, Chief Legal Officer & Secretary

FAQs

What is Seres Therapeutics Inc. share price today?

Seres Therapeutics Inc. share price today is $4.87 as on August 8, 2026 at 8:45 am IST at the close of the market. Seres Therapeutics Inc. share today touched a day high of $5.19 and a low of $4.82.

What is the 52 week high and 52 week low for Seres Therapeutics Inc. share?

Seres Therapeutics Inc. share touched a 52 week high of $29.98 on January 1, 1970 and a 52 week low of $4.59 on January 1, 1970. Seres Therapeutics Inc. stock price today i.e. August 8, 2026 at 8:45 am IST is closed at $4.87,which is 83.76% down from its 52 week high and 6.10% up from its 52 week low.

What is Seres Therapeutics Inc.'s market capitalisation today?

Seres Therapeutics Inc. market capitalisation is $0.00T as on August 8, 2026 at 8:45 am IST.

How to invest in Seres Therapeutics Inc. Stock (MCRB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Seres Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Seres Therapeutics Inc. Shares that will get you 0.3080 shares as per Seres Therapeutics Inc. share price of $4.87 per share as on August 8, 2026 at 8:45 am IST.

What is the minimum amount required to buy Seres Therapeutics Inc. Stock (MCRB) from India?

Indian investors can start investing in Seres Therapeutics Inc. (MCRB) shares with as little as ₹95.2 or $1 (as of August 9, 2026 at 2:39 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹952.00 in Seres Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on August 9, 2026 at 2:39 pm IST). Based on Seres Therapeutics Inc. share’s latest price of $4.87 as on August 8, 2026 at 8:45 am IST, you will get 2.0534 shares of Seres Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Seres Therapeutics Inc. has given to Indian investors in the last 5 years?

Seres Therapeutics Inc. stock has given -96.54% share price returns and 27.7% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?